Tag: cetuximab mFOLFOX6 regimen

Home / cetuximab mFOLFOX6 regimen

Categories

Encorafenib with cetuximab and mFOLFOX6 is approved by the USFDA for metastatic colorectal cancer with a BRAF V600E mutation

On December 20, 2024, the Food and Drug Administration conferred accelerated approval for encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in conjunction with cetuximab and mF...
cetuximab-mfolfox6-regimen

Scan the code